Timing of Oocyte Retrieval and Micro Testicular Sperm Extraction

Timing of Oocyte Retrieval and Micro Testicular Sperm Extraction: Does it Make a Difference? A Single-center Retrospective Cohort

This is a retrospective study to assess outcomes of micro-TESE performed 24 or 48 hours before oocyte retrieval and ICSI.

Study Overview

• Status: Completed
• Conditions: Microdissection Testicular Sperm Extraction

Detailed Description

This retrospective study evaluates patients undergoing ICSI following micro-TESE. Participants are assigned to two groups based on the interval between sperm extraction and oocyte retrieval (24 vs. 48 hours). Clinical and embryological outcomes from the first embryo transfer will be assessed.

• Study Type: Observational
• Enrollment (Actual): 129

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montreal, Quebec, Canada, H4P 2S4
      • Clinique ovo

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Men who underwent a micro-TESE for IVF treatment

Description

Inclusion Criteria:

• Men who underwent a micro-TESE at the OVO clinic from June 2015 to January 2025.
• Patients with non-obstructive azoospermia (NOA), (absence of spermatozoa in multiple semen analyses)
• Patients with cryptozoospermia, (presence of a small number of spermatozoa detectable only after semen centrifugation)
• Patients with oligoasthenoteratozoospermia (OAT), (sperm concentration of less than 15 million/mL, reduced motility and abnormal morphology)

Exclusion Criteria:

• Patients who did not have any sperm noted following micro-TESE
• Use of donor sperm or oocytes
• Frozen sperm or oocytes
• Same day oocyte retrieval and sperm extraction
• Reversible cause of cryptozoospermia (i.e presence of a varicocele, febrile illness, or recent toxin exposure) Partial genital tract obstruction (i.e post-vaso-vasostomy, post-vasoepididymostomy, and low volume cryptozoospermia with ejaculatory duct obstruction)

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of live births following ICSI with micro-TESE either 24 or 48 hours prior to oocyte retrieval	For IVF performed from June 2015 to January 2025

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of fertilized oocytes with two pronuclei (2PN)	For IVF performed from June 2015 to January 2025
Percentage of usable blastocyst (defined as frozen and transferred blastocysts)	For IVF performed from June 2015 to January 2025
Pregnancy rate based on positive β-hCG	For IVF performed from June 2015 to January 2025

Collaborators and Investigators

• Sponsor: Clinique Ovo
• Investigators: Principal Investigator: Isaac-Jacques Kadoch, MD, Clinique ovo

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2025
• Primary Completion (Actual): November 30, 2025
• Study Completion (Actual): November 30, 2025

Study Registration Dates

• First Submitted: November 17, 2025
• First Submitted That Met QC Criteria: December 3, 2025
• First Posted (Actual): December 5, 2025

Study Record Updates

• Last Update Posted (Actual): December 5, 2025
• Last Update Submitted That Met QC Criteria: December 3, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: In vitro fertilization; intracytoplasmic sperm injection; Nonobstructive Azoospermia; oligoasthenoteratozoospermia; cryptozoospermia
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Genital Diseases, Male; Male Urogenital Diseases; Infertility, Male; Infertility; Oligospermia; Azoospermia, Nonobstructive
• Other Study ID Numbers: Micro-TESE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No